Novartis Sues Intas Over Patent Infringement Claims

Novartis AG sued Intas Pharmaceuticals Ltd. for patent infringement, claiming it sought U.S. approval to sell a generic version of the immunosuppressant drug Myfortic before Novartis’s patents expired.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.